Gene Solutions has formalized a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP-accredited laboratory with a well-established footprint across all over China.

• SPOT-MAS : The first clinically validated MCED test in Asia, enabling early detection of multiple cancers from a single blood sample.
• SPOT-MAS Lung: A specialized screening solution designed for the early detection of lung cancer.
• K-4CARE: A comprehensive genomic and transcriptomic profiling platform with integrated ctDNA-based MRD (Molecular Residual Disease) monitoring, supporting personalized treatment strategies and long-term disease management.

These technologies will enhance Topgen's oncology portfolio and enable broader access to cutting-edge cancer screening and monitoring tools across its hospital network.

" Besides the expected enriched oncology portfolio and enhanced technology generated from the collaboration with Gene Solutions, the partnership is expected to deliver broader strategic value. For example, the co-developed technology can benefit both parties; the multi-regional clinical trial and validation on fragmentomics can accelerate the product licensing process for both parties; Moreover, our joint efforts to expand into international markets will strongly support each company's overseas business strategy." said Herry Shen, Chairman of Topgen's Board.

"Top g en's robust infrastructure and clinical reach make them an ideal partner to scale our innovations," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "This collaboration is designed to bring advanced cancer genomics to the forefront of clinical care across the extensive hospital network served by Topgen in China."

The collaboration will emphasize clinical validation, translational research, and coordinated commercialization—with the shared goal of improving cancer patient outcomes throughout the region.